Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins
- PMID:7200504
Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins
Abstract
Animal cholesterol synthesis shows a marked diurnal variation, a phenomenon, at the moment, not known to occur in man. Since cholesterol precursors in serum reflect overall cholesterol synthesis in many conditions, a 24-hr profile of squalene and methyl sterols was studied in plasma lipoproteins in order to demonstrate whether these cholesterol precursors could exhibit a diurnal cycling in healthy human subjects. During the 24-hr period, lipoproteins of density < 1.006 g/ml transported 30-50% of the plasma squalene. Free methyl sterols were found mainly in low density lipoproteins (LDL) and esterified methyl sterols in LDL and high density lipoproteins (HDL). Postprandial hyperlipidemia at noon was associated with an inconsistent increase of the squalene and free methyl sterol concentrations in the lipoproteins of density < 1.006 g/ml. In terms of micro g per mg of cholesterol, the precursor contents were, however, low in each lipoprotein during the daytime. During the night and early morning, the values were several times higher. Thus the peak plasma squalene and methyl sterol contents occurred at midnight and 4 am. The highest variation was found for squalene in the density class < 1.006 g/ml and for lanosterol and diunsaturated dimethyl sterol in LDL and HDL. For different methyl sterols, the mean diurnal variation was 3.5- to 6.9-fold in LDL, 2.0- to 4.5-fold in HDL, and 2.6- to 3.6-fold in the density class < 1.006 g/ml. The respective values for squalene were 2.2, 1.4, and 2.9. Esterified methyl sterols varied slightly in the density class < 1.006 g/ml only, and the percentage esterification exhibited a diurnal fluctuation that was the reciprocal of that of free methyl sterol levels. The rapid and marked diurnal fluctuation of squalene and free methyl sterols in plasma lipoproteins suggests that these precursors are metabolized on and off lipoproteins. The variation is most likely caused by changes in cholesterol synthesis, inferring that circadian rhythm also regulates human cholesterol production.-Miettinen, T. A. Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins.
Similar articles
- Increased amounts of cholesterol precursors in lipoproteins after ileal exclusion.Koivisto PV, Miettinen TA.Koivisto PV, et al.Lipids. 1988 Oct;23(10):993-6. doi: 10.1007/BF02536349.Lipids. 1988.PMID:3200122
- Cholesterol precursors and their diurnal rhythm in lipoproteins of patients with jejuno-ileal bypass and ileal dysfunction.Miettinen TA.Miettinen TA.Metabolism. 1985 May;34(5):425-30. doi: 10.1016/0026-0495(85)90207-0.Metabolism. 1985.PMID:4039401
- Diurnal variation of plasma methyl sterols and cholesterol in the rat: relation to hepatic cholesterol synthesis.Strandberg TE, Tilvis RS, Miettinen TA.Strandberg TE, et al.Lipids. 1984 Mar;19(3):202-5. doi: 10.1007/BF02534798.Lipids. 1984.PMID:6538923
- Squalene and noncholesterol sterols in serum and lipoproteins of children with and without familial hypercholesterolemia.Ketomäki A, Gylling H, Siimes MA, Vuorio A, Miettinen TA.Ketomäki A, et al.Pediatr Res. 2003 Apr;53(4):648-53. doi: 10.1203/01.PDR.0000055771.28409.40. Epub 2003 Jan 29.Pediatr Res. 2003.PMID:12612218
- Steroidal triterpenes of cholesterol synthesis.Ačimovič J, Rozman D.Ačimovič J, et al.Molecules. 2013 Apr 4;18(4):4002-17. doi: 10.3390/molecules18044002.Molecules. 2013.PMID:23558541Free PMC article.Review.
Cited by
- Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond.Grewal T, Buechler C.Grewal T, et al.Int J Mol Sci. 2022 Jan 19;23(3):1070. doi: 10.3390/ijms23031070.Int J Mol Sci. 2022.PMID:35162992Free PMC article.Review.
- Hypoxia truncates and constitutively activates the key cholesterol synthesis enzyme squalene monooxygenase.Coates HW, Capell-Hattam IM, Olzomer EM, Du X, Farrell R, Yang H, Byrne FL, Brown AJ.Coates HW, et al.Elife. 2023 Jan 19;12:e82843. doi: 10.7554/eLife.82843.Elife. 2023.PMID:36655986Free PMC article.
- Reduction of High Cholesterol Levels by a Preferably Fixed-Combination Strategy as the First Step in the Treatment of Hypertensive Patients with Hypercholesterolemia and High/Very High Cardiovascular Risk: A Consensus Document by the Italian Society of Hypertension.Grassi G, Del Pinto R, Agabiti Rosei C, Agnoletti D, Borghi C, Cicero AFG, De Ciuceis C, Desideri G, Grassi D, Muiesan ML, Paini A, Salvetti M, Tocci G, Veglio F, Volpe M, Ferri C.Grassi G, et al.High Blood Press Cardiovasc Prev. 2022 Mar;29(2):105-113. doi: 10.1007/s40292-021-00501-6. Epub 2022 Jan 3.High Blood Press Cardiovasc Prev. 2022.PMID:34978703Free PMC article.
- Cholesterol absorption status and fasting plasma cholesterol are modulated by the microsomal triacylglycerol transfer protein -493 G/T polymorphism and the usual diet in women.Wolff E, Vergnes MF, Defoort C, Planells R, Portugal H, Nicolay A, Lairon D.Wolff E, et al.Genes Nutr. 2011 Feb;6(1):71-9. doi: 10.1007/s12263-010-0174-x. Epub 2010 Apr 1.Genes Nutr. 2011.PMID:21437032Free PMC article.
- Effects of pravastatin on plasma and urinary mevalonate concentrations in subjects with familial hypercholesterolaemia: a comparison of morning and evening administration.Nozaki S, Nakagawa T, Nakata A, Yamashita S, Kameda-Takemura K, Nakamura T, Keno Y, Tokunaga K, Matsuzawa Y.Nozaki S, et al.Eur J Clin Pharmacol. 1996;49(5):361-4. doi: 10.1007/BF00203778.Eur J Clin Pharmacol. 1996.PMID:8866629Clinical Trial.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical